Signaturefd LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX

Signaturefd LLC boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 242.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,266 shares of the company’s stock after purchasing an additional 2,312 shares during the period. Signaturefd LLC’s holdings in Vaxcyte were worth $106,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in PCVX. AlphaQuest LLC acquired a new stake in Vaxcyte during the first quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Vaxcyte in the first quarter valued at approximately $35,000. Parallel Advisors LLC lifted its stake in Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after purchasing an additional 1,071 shares in the last quarter. IFP Advisors Inc grew its stake in shares of Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after buying an additional 1,306 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its holdings in shares of Vaxcyte by 81.6% in the 1st quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after buying an additional 867 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Up 6.3%

Vaxcyte stock opened at $42.66 on Friday. The firm’s 50-day simple moving average is $32.73 and its 200 day simple moving average is $34.98. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $118.62. The firm has a market capitalization of $5.54 billion, a PE ratio of -10.38 and a beta of 1.12.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the firm earned ($1.10) EPS. On average, research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vaxcyte in a research report on Saturday, September 27th. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, September 12th. They set a “neutral” rating and a $38.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.